talquetamab,belantamab mafodotin
gsk,janssen
['belantamab', 'talquetamab', 'arca ', 'arca, (-arcade)']
master presenter ajai chari presenting talquetamab a bispecific antibody targeting gprc5d. amazing 74% orr and even more remarkable low infection rates grade 3/4 at 17% and 12%. this is remarkable and may likely be the next bispecific and first gprc5d available #ash22 #mediq22ash 
Hematologist, Myeloma Expert, Communication Enthusiast. Professor at TGen/City of Hope and Chief Medical Officer of the International Myeloma Foundation